Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 21.51 CNY 1.13% Market Closed
Market Cap: 11.3B CNY
Have any thoughts about
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Zhejiang Wolwo Bio-Pharmaceutical Co Ltd stock under the Base Case scenario is 25.8 CNY. Compared to the current market price of 21.51 CNY, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is Undervalued by 17%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
25.8 CNY
Undervaluation 17%
Relative Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Multiples

12.4
P/S
P/S
Price to Sales
12.4
vs History
90
vs Industry
13
Median 3Y
22.3
Median 5Y
30.7
Industry
2.5
Forward
11.5
More Details
36.1
P/E
P/E
Price to Earnings
36.1
vs History
87
vs Industry
14
Median 3Y
59.4
Median 5Y
74
Industry
21.8
Forward
32.3
More Details
38.7
P/OCF
P/OCF
Price to OCF
38.7
vs History
77
vs Industry
15
Median 3Y
55.5
Median 5Y
73.9
Industry
16.1
More Details
73.3
P/FCFE
P/FCFE
Price to FCFE
73.3
vs History
88
vs Industry
8
Median 3Y
115
Median 5Y
145.9
Industry
23.8
More Details
5
P/B
P/B
Price to Book Value
5
vs History
87
vs Industry
16
Median 3Y
9.8
Median 5Y
13.9
Industry
2.1
More Details
11.1
EV/S
EV/S
Enterprise Value to Sales
11.1
vs History
90
vs Industry
13
Median 3Y
21
Median 5Y
29.5
Industry
2.7
Forward
10.3
More Details
11.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.7
vs History
90
vs Industry
18
Median 3Y
22.2
Median 5Y
31
Industry
5.2
More Details
31
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31
vs History
87
vs Industry
12
Median 3Y
52.3
Median 5Y
68.1
Industry
13.5
Forward
23.1
More Details
31
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
31
vs History
87
vs Industry
16
Median 3Y
52.3
Median 5Y
68.1
Industry
16.8
Forward
22.7
More Details
34.4
EV/OCF
EV/OCF
Enterprise Value to OCF
34.4
vs History
80
vs Industry
17
Median 3Y
52
Median 5Y
71
Industry
15.2
More Details
60.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
60.5
vs History
90
vs Industry
8
Median 3Y
107.9
Median 5Y
141.7
Industry
19.3
More Details
7.4
EV/IC
EV/IC
Enterprise Value to IC
7.4
vs History
90
vs Industry
13
Median 3Y
16.9
Median 5Y
25.6
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
11.3B CNY 12.4 36.1 31 31
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/E Multiple
Earnings Growth P/E to Growth
CN
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Average P/E: 32.7
36.1
59%
0.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Average EV/EBITDA: 416.7
31
97%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Average EV/EBIT: 1 813.2
31
101%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.